BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//OncoPlanning//Event//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:f99851b7-f97c-40e2-9aa2-2fb767e0ed48@oncoplanning
DTSTAMP:20260524T190328Z
DTSTART;VALUE=DATE:20260609
DTEND;VALUE=DATE:20260611
SUMMARY:World TPD & Induced Proximity Summit South Korea
DESCRIPTION:With the first anticipated PROTAC approval and multiple candidates advancing through clinical trials\, 2026 is going to be a pivotal year for the global targeted-protein degradation (TPD) industry. This global momentum is fueling Korea’s own TPD boom: over $144M raised in the past 12 months\, alongside strategic collaborations from leaders like Ubix Therapeutics\, Prazer Therapeutics\, and Bridge Biotherapeutics.\n\nThe inaugural World TPD & Induced Proximity Summit South Korea is the only event dedicated to gathering the Asian biopharma focused on end-to-end TPD drug development. Featuring key international opinion leaders\, deep dives into preclinical and clinical strategy\, and expanded content on molecular glues and novel E3 ligases\, this summit is your chance to de-risk your pipelines\, learn from international experts\, and build the global collaborations needed to advance best-in-class TPD therapeutics.\n\nPart of the World Targeted Therapeutics Summit in South Korea organized by Hanson Wade\, this is your opportunity to converge with peers working on antibody-drug conjugates (ADCs)\, Bispecifics\, and T-cell engagers\, who aim to turn South Korea into the next major global hub for biopharma innovation in targeted therapeutics.
LOCATION:COEX Magok Lewest\, Seoul\, South Korea
URL:https://worldtpd-kr.com/?utm_source=internal-event&utm_medium=affiliate&utm_campaign=web-visitors&utm_content=launch/ev-62993/banner-internal-event
END:VEVENT
END:VCALENDAR